Counterregulatory actions of angiotensin-(1-7). 1997

C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
Hypertension Center, the Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC 27157-1032, USA.

Angiotensin (Ang)-(1-7) is a bioactive component of the renin-angiotensin system that is formed endogenously from either Ang I or Ang II. The first actions described for Ang-(1-7) indicated that the peptide mimicked some of the effects of Ang II, including the release of prostanoids and vasopressin. However, Ang-(1-7) is devoid of vasoconstrictor, central pressor, or thirst-stimulating actions. In fact, new findings reveal depressor, vasodilator, and antihypertensive actions that may be more apparent in hypertensive animals or humans. Thus, the accumulating evidence suggests that Ang-(1-7) may oppose the actions of Ang II either directly or by stimulation of prostaglandins and nitric oxide. These observations are significant because they may explain the effective antihypertensive action of converting enzyme inhibitors in a variety of non-renin-dependent models of experimental and genetic hypertension as well as most forms of human hypertension. In this context, studies in humans and animals showed that the antihypertensive action of converting enzyme inhibitors correlated with increases in plasma levels of Ang-(1-7). In this review, we summarize our knowledge of the mechanisms accounting for the counterregulatory actions of Ang-(1-7) and elaborate on the emerging concept that Ang-(1-7) functions as an antihypertensive peptide within the cascade of the renin-angiotensin system.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000803 Angiotensin I A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
January 1993, Peptides,
C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
April 1997, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
April 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
July 1998, Journal of cardiovascular pharmacology,
C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
April 1994, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
April 2013, Clinical science (London, England : 1979),
C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
February 1992, Hypertension (Dallas, Tex. : 1979),
C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
July 1995, The American journal of physiology,
C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
January 2018, Hypertension (Dallas, Tex. : 1979),
C M Ferrario, and M C Chappell, and E A Tallant, and K B Brosnihan, and D I Diz
January 1994, Brain research bulletin,
Copied contents to your clipboard!